Arlington Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,579
Closed -$247K – 41
2026
Q2
$247K Hold
1,579
– – 0.45% 40
2026
Q1
$241K Buy
+1,579
New +$242K 0.48% 25
2025
Q4
– Sell
-39,628
Closed -$5.08M – 38
2025
Q3
$5.08M Buy
39,628
+723
+2% +$88.2K 1.76% 19
2025
Q2
$4.71M Sell
38,905
-1,977
-5% -$223K 1.74% 12
2025
Q1
$4.56M Buy
40,882
+9,730
+31% +$1.04M 1.79% 19
2024
Q4
$3.03M Sell
31,152
-6,404
-17% -$683K 1.18% 49
2024
Q3
$4.32M Buy
37,556
+6,404
+21% +$727K 1.69% 24
2024
Q2
$3.32M Buy
31,152
+1,503
+5% +$151K 1.65% 15
2024
Q1
$2.87M Hold
29,649
– – 1.46% 47
2023
Q4
$2.99M Buy
29,649
+623
+2% +$60.1K 0.86% 41
2023
Q3
$2.96M Buy
+29,026
New +$2.95M 1.21% 16
2022
Q3
– Sell
-314
Closed -$27K – 430
2022
Q2
$27K Hold
314
– – 0.01% 298
2022
Q1
$28K Hold
314
– – 0.01% 297
2021
Q4
$27K Buy
+314
New +$26.1K 0.01% 338
2021
Q3
– Sell
-27
Closed -$2K – 399
2021
Q2
$2K Hold
27
– – ﹤0.01% 309
2021
Q1
$2K Buy
+27
New +$2.42K ﹤0.01% 375

Other funds holding NVS

Arlington Partners's NVS Position: Q3 2026 in Review

Arlington Partners sold out of Novartis (NVS) in Q3 2026, closing a stake of 1,579 shares — an estimated $247K sold.

Arlington Partners first reported a position in NVS in Q1 2021 and held it in 16 quarters. The position peaked at $5.08M in Q3 2025. 1,548 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Arlington Partners reported no remaining Novartis position as of Q3 2026 after selling out during the quarter.
  • Arlington Partners sold 1,579 Novartis shares in Q3 2026, an estimated $247K.
  • Arlington Partners first reported a position in Novartis in Q1 2021 and held it in 16 quarters.
  • Arlington Partners's Novartis position peaked at $5.08M in Q3 2025.
  • 1,548 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Arlington Partners's 13F filing for Q3 2026, filed 20 Oct 2026.